AzTrials
AzTrials

PneumoniaPOP-PCRNCT03752320

Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery

An observational study of Pneumonia and Bacterial Pneumonia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: In thoracic surgery, postoperative pneumonia (POP) is the leading cause of postoperative morbidity and mortality. The clinical diagnosis of POP is difficult and conventional microbiological diagnostic tests perform poorly. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pneumonia, Bacterial Pneumonia
How many people
200 participants
Where
1 siteFrance
Study dates
7 Feb 2019to Feb 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All the consecutive adult patients hospitalized for lung surgical resection (except surgical resection indicated for infectious disease) for one year at Tenon hospital, a University teaching in Paris, Assistance publique - Hôpitaux de Paris, France. About 200-250 patients undergo a thoracic surgery per year and are supported in the thoracic surgery department of Tenon hospital. If we consider a 25% incidence rate of post operative pneumonia, we expect 50-60 patients to be included during the study period.

Who may be able to join

  • Adult patients hospitalized for lung surgical resection
  • Consenting to research

Who cannot join

  • surgical resection indicated for infectious disease

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • Service de Réanimation et USC médico-chirurgicale Hôpital Tenon, AP-HP

    Paris, Île-de-France Region, 75020

    Muriel Fartoukh, MD PhD, 0033 (0) 1 56 01 65 72, muriel.fartoukh@aphp.fr

    MD, 0033 (0) 7 72 77 72 20, matthieu.turpin@aphp.fr

    Recruiting

Other trials in France

About this study

Official title: Usefulness of a Multiplex Polymerase Chain Reaction (mPCR) Assay for the Diagnosis of Postoperative Pneumonia After Thoracic Surgery

Background: In thoracic surgery, postoperative pneumonia (POP) is the leading cause of postoperative morbidity and mortality. The clinical diagnosis of POP is difficult and conventional microbiological diagnostic tests perform poorly. The contribution of molecular diagnostic tests (multiplex PCR, mPCR) should be evaluated to optimize the diagnostic and therapeutic management of POP.

Objectives: The main objective is to describe the microbiological relationship between the existence of pre- (if available) and intra-operative bronchial and pulmonary bacterial colonization and the occurrence of POP. The secondary objectives are to analyze the contribution of the mPCR for the diagnosis of POP and to validate the predictive factors of POP described in the literature Material and methods: A monocentric prospective non-interventional research with minimal risks and constraints. The study population is represented by all the consecutive adult patients hospitalized for lung surgical resection (except surgical resection indicated for infectious disease) during one year. The preoperative respiratory samples within the 3 preceding months (date and type, pathogen and threshold) are recorded, if available. Intra-operative bronchial aspirate is performed for direct examination and culture (pathogen and threshold) and mPCR (PCR1). A mPCR is optionally performed on the surgical specimen (PCR2). In case of postoperative clinical suspicion of POP, invasive or non invasive samples of respiratory tract secretions are obtained for direct examination and culture (pathogen, threshold) and mPCR (PCR3). A clinical pulmonary infection score (CPIS) is calculated by integrating the results of conventional tests (CPIS1) and mPCR (CPIS2).

The pre / intra operative and postoperative microbiological relationship will be described qualitatively and quantitatively and analyzed using correlation tests. Concordances and discrepancies between conventional tests and mPCR will be studied to analyze the contribution of molecular tests in this context.

Read the detailed description

Background: Post operative pneumonia (POP) is a common and severe complication associated with a high morbidity and mortality, regardless of the type of surgery. In thoracic surgery, the global incidence of POP is estimated at 25%. Pre-operative bronchial and pulmonary bacterial colonization appear as a major risk factor for the occurrence of POP, according to the literature.

The diagnosis of POP is challenging, because the usual diagnostic criteria are poorly relevant and clinical diagnostic scores are not validated, which may explain the scarcity of published data in the literature.

Patients' fragility and comorbid conditions mainly due to smoking limit the opportunity to perform invasive microbiological diagnostic tests, and those latter perform poorly. Altogether, the pathogen(s) involved are identified in 14% to 50%.

The evaluation of the diagnostic contribution of molecular diagnostic tests (mPCR) is important in this context. Molecular diagnostic tests offer better performance (sensitivity and sensibility) than conventional test, and the results are not affected by previous exposure to antibiotics. These tests could be useful to analyze the microbiological relationship between pre or per-operative bronchial and pulmonary colonization and postoperative infection, to optimize the diagnostic and the management of POP after thoracic surgery.

Materials and methods: In this study, The investigators aim to describe the microbiological relationship between the existence of pre- (if available) and intra-operative bronchial and pulmonary bacterial colonization and the occurrence of POP. The investigators also intend to analyze the contribution of mPCR for the diagnosis of POP.

For more precision, primary and secondary outcomes descriptions are fully detailed in the corresponding section.

The investigators perform a monocentric prospective non-interventional research with minimal risks and constraints. The study population is represented by all the consecutive adult patients hospitalized for lung surgical resection (except surgical resection indicated for infectious disease) during one year at Tenon Hospital, a University teaching hospital in Paris, France. About 200 patients per year undergo a lung surgical resection. Depending on the POP incidence, the number of patients suspected of POP may vary between 25 and 50 during the study period. Study duration participation corresponds to the hospital length of stay.

PCR Film Array Pneumonia is the molecular test used in this study. It is designed to detect the most common and critical pathogens of pneumonia (bacteria, virus). The results are reported quantitatively. Patients' management is in line with recommendations and not modified by the research. The expected risks are those of the usual care.

The practical progress of the study is defined by:

  • Preoperative. Patients' clinical characteristics, respiratory status and expected surgery data are collected. The preoperative respiratory samples (date and type, pathogen and threshold) are recorded if available within the 3 preceding months
  • Per-operative. Intra-operative bronchial aspirate is performed for direct examination and culture (pathogen and threshold) and mPCR (PCR1). Surgery characteristics are collected. Per-operative antibioprophylaxis is in line with recommendations.
  • Post operative. Identification of post operative complications (respiratory and extra respiratory) including POP. POP diagnosis is based on clinical and microbiological data (Clinical Pulmonary Infection Score). In case of clinical suspicion of POP, respiratory samples are performed for direct examination and culture (pathogen and threshold) and mPCR (PCR2). A CPIS score is calculated with conventional microbiological tests results (CPIS 1) and PCR results (CPIS2). Hospital health care and vital status at discharge are recorded.

Primary and secondary outcomes measures are fully detailed in the corresponding section.

Statistical analysis: The statistical analysis will be performed at the end of the study. The characteristics of the patients will be described and compared between two groups, i.e. patients with POP and patients without POP. Qualitative variables will be described by size and frequency, and quantitative variables by mean and standard deviation or median and inter-quartile range. Between-groups comparisons will be performed using a Chi2 or a Fisher exact test for qualitative variables, and a Student t test or Mann-Whitney U test for the quantitative variables.

For the primary outcome, the proportion of patients for whom the intra operative colonization strain and the postoperative infection strain are the same will be calculated (with their 95% confidence interval).

For the secondary outcomes, the overall concordance rate, and the qualitative and quantitative diagnostic discrepancies will be calculated with their 95% confidence interval between conventional and molecular tests. The proportions of patients with appropriate antibiotic therapy and with targeted antibiotic therapy will be estimated and compared between conventional and molecular tests.

The predictive factors for POP occurrence will be assessed by a logistic regression model.

Keywords
Postoperative pneumonia, Thoracic surgery, Multiplex PCR, Bacterial and pulmonary colonization, Diagnosis, Mortality
Medical subject headings
Pneumonia, Pneumonia, Bacterial, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03752320
Study groupRoleWhat they receive
POP+ and POP-POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients in whom the preoperative microorganism (colonization) is the same than that identified in POP.

    The diagnosis of POP is based on the CPIS using clinical data and microbiology (CPIS1 and CPIS2).

    The final diagnosis is:

    Certain: Clinical evidence of pneumonia, quantitative positive respiratory tract samples (RTS) above the thresholds Probable: Strong clinical suspicion (CPIS>6), RTS below the thresholds, no ongoing or recently introduced antibiotics (atb); or RTS below the thresholds with ongoing or recently introduced atb, regardless the clinical suspicion Possible: Low clinical suspicion (CPIS≤6), RTS below the thresholds, no ongoing or recently introduced atb; or CPIS≤6, negative RTS and ongoing or recently introduced atb Unlikely: Negative RTS with no ongoing or recently introduced atb; or CPIS≤6, negative RTS and ongoing or recently introduced atb.

    Comparing CPIS1 and CPIS2, we also asses the diagnostic contribution of molecular tests

    Measured: Defined by the patient's hospitalization, from surgery to hospital discharge, until 28 days of follow up

Secondary outcomes (3)
  1. The rate of diagnostic concordance between conventional and molecular tests in the context of post operative pneumonia in thoracic surgery.

    Conventional and mPCR tests concordance is defined by the identification of the same microbiological species above or below the thresholds positivity for both tests.

    Qualitatively minor discrepancy is defined by different microbiological species below the thresholds for both tests.

    Qualitatively major discrepancy is defined by different microbiological species with both tests and below the threshold for one and above for the other.

    Quantitatively minor discrepancy is defined by the identification of the same microbiological species with both tests but below the positivity threshold for one and above for the other.

    Quantitatively major discrepancy is defined by the identification of different microbiological species above the thresholds for both tests.

    Measured: Defined by the patient's hospitalization, from surgery to hospital discharge, including the period management of post operative pneumonia, until 28 days of follow up

  2. Mesure of the theoretical impact of molecular diagnostic test results on the antibiotics use.

    A panel of independent clinicians will suggest a fictive antibiotic therapy based on mPCR results.

    The proportions of patients with appropriate antibiotic therapy and patients with targeted antibiotic therapy will be compared, according to the results of the microbiological tests (conventional vs. mPCR) for the initial empirical antibiotic therapy, and the secondary antibiotic therapy (at 24 and 48h).

    Measured: Defined by the patients' hospitalization, from surgery to hospital discharge, including the period management of post operative pneumonia, until 28 days of follow up

  3. The measurement of the association of general characteristics, pneumological and functional respiratory characteristics related to the surgical procedure with the occurrence of POPs in the entire study population.

    The predictive factors of post operative pneumonia described in the literature General, lung functional and surgical characteristics of patients will be recorded at baseline.

    Measured: Defined by the patient's hospitalization, from surgery to hospital discharge, including the period management of post operative pneumonia, until 28 days of follow up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2018
  2. Study start7 Feb 2019
  3. Primary completionFeb 2020 (estimated)
  4. Study completionFeb 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03752320
Sponsor's protocol ID
APHP180010
Other IDs
2018-A01908-47
Acronym
POP-PCR
Status last verified
Jul 2019
First submitted
30 Aug 2018
Last updated
25 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: individual participant data collected in this study will be used for publication.

Questions about this trial

What is this clinical trial studying?

An observational study of Pneumonia and Bacterial Pneumonia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Muriel Fartoukh, MD PhD (0033 (0) 1 56 01 65 72, muriel.fartoukh@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients in whom the preoperative microorganism (colonization) is the same than that identified in POP. (time frame: Defined by the patient's hospitalization, from surgery to hospital discharge, until 28 days of follow up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in